When: Flush to $250-252

Then: Reserve 2/3 for deeper entry

HOLD with trailing stop at 250.16; staged adds only into pullback toward 257 to 260; do not chase at current levels or add on breakout above 269

• Low-volume advance at resistance (2.76 million shares, 16.4% above 200 SMA) is a distribution signature, not stealth accumulation - breakouts that fail typically exhibit this exact pattern
• Multiple expansion from 16x to 19-20x forward P/E requires simultaneous realization of every bullish catalyst: Skyrizi/Rinvoq ramp, no pipeline setbacks, no IRA expansion, no biosimilar acceleration, no margin compression
• Trailing stop at 250.16 defines where thesis breaks; if wrong at current levels, looking at 5.7% loss; aggressive add protocol would create substantially larger drawdown before stop discipline
• 0.28 beta cuts both ways - less upside in risk-on AND less downside in risk-off; higher rates compress all multiples including dividend compounders with $90 billion in intangibles
• FCF has trended down from 4.88 billion (Q2 2025) to 3.11 billion (Q2 2026) across two consecutive quarters - sustained pattern, not working capital timing
• If structural FCF is 13-14 billion annualized (not 17.82 billion), dividend coverage drops from 1.45x to 1.05-1.10x - uncomfortably thin for 468 billion market cap with 70 billion in total debt
• New high on lowest volume in visible window is a warning sign, not validation; new highs with expanding volume are confirmation
• Six of seven positive articles is consistent with local tops - uniformly bullish news flow is a coincident indicator, not leading
• Aggressive add protocol at 260-263 is buying near resistance; breakout above 269 is worst entry in technical analysis; trader protocol of waiting for 250-252 buys weakness at confluence support

→ vs aggressive: Volume defense mislabeled as stealth accumulation when institutions building quietly buy on weakness, not at all-time highs 16.4% above the 200 SMA - this is low-volume advance at resistance, not sustainable accumulation

→ vs aggressive: Multiple expansion to 19-20x P/E requires stacked bullish assumptions with no margin for error on a mature pharma facing patent cliffs, biosimilar erosion, IRA pressure, and 64 billion net debt

→ vs aggressive: Wait for pullback is recency bias argument ignores that patience preserves capital; aggressive add protocol would face substantially larger drawdown if trailing stop at 250.16 is hit

→ vs aggressive: Hawkish Fed tailwind oversold - 0.28 beta means less upside in risk-on AND less downside in risk-off; higher rates compress all multiples including long-dated cash flows discounted at higher rates

→ vs aggressive: H1'26 FCF concern dismissed as working capital timing but two-quarter declining trend (4.88B to 3.11B) is structural; 13-14B annualized FCF would leave dividend coverage at 1.05-1.10x

→ vs aggressive: New highs as validation is classic anchoring bias - new high on lowest volume is distribution signature preceding corrections, not trend confirmation

→ vs aggressive: Institutional news flow argument is backward-looking - uniformly bullish sentiment at 6 of 7 positive is coincident indicator typical of local tops

→ vs aggressive: Add protocol design flaw: buying at 260-263 near resistance immediately underwater if price pulls to 250 trailing stop; breakout above 269 is worst possible technical entry

HOLD with refined protocol: maintain trailing stop at 250.16, cap additional adds at 1/3 of intended size until breakout confirmation above 269.23 with volume > 4.5M shares, and monitor Q3 2026 FCF as decisive data point for trailing stop adjustment.

• Trailing stop at 250.16 is non-negotiable and serves as absolute thesis-break level
• Add protocol of 1/3 at 257-260 and 2/3 reserved is well-calibrated; breakout trigger refined to clean close above 269.23 with volume > 4.5M shares
• Q3 2026 FCF is critical data point: if recovers to ~4B+ validates working capital timing explanation; if continues declining, tighten trailing stop to 252
• Forward P/E of 16.3 with PEG of 0.54 supports that ABBV is appropriately priced, not structurally mispriced
• 0.28 beta, 1.45x dividend coverage, and 2.6% yield provide meaningful structural supports in current macro environment
• Q1-Q2 2026 FCF decline to 3.56B and 3.11B respectively signals potential structural FCF level of 13-14B annualized, dropping dividend coverage to 1.05-1.10x
• Accumulation pattern on 2.76M shares is unfalsifiable and not analytically rigorous
• Multiple expansion to 19-20x versus MRK/LLY comparisons is analytically sloppy given Skyrizi/Rinvoq biosimilar and IRA overhang risks
• Rinvoq pediatric approval, VRAYLAR real-world data, migraine franchise progress, and AI drug discovery positioning are constructive forward catalysts
• Six of seven constructive articles represents sentiment that can persist in structural bull markets rather than forming immediate local top
• Current entry point is poor with risk-reward only 1:1 to upper Bollinger Band at 269.23

→ vs aggressive: Multiple expansion thesis comparing ABBV to MRK/LLY is analytically sloppy; MRK has Keytruda runway through early 2030s and LLY owns GLP-1 monopoly economics, while ABBV's Skyrizi/Rinvoq faces maturing portfolio and IRA overhang

→ vs aggressive: Stealth accumulation framing for 2.76M share tape is unfalsifiable; any low-volume move can be retroactively labeled as accumulation, which is storytelling not analysis

→ vs aggressive: Dismissal of FCF decline as working capital timing is weak; two consecutive quarters of FCF decline to 3.56B and 3.11B warrants real weight in position sizing

→ vs conservative: New highs on low volume being automatically bearish is too categorical; in mature large-cap pharma with institutional participants, this is inconclusive rather than deterministically bearish

→ vs conservative: Overweighting bearish macro threats when Fed is hawkish against falling recession probability, buoyant risk appetite, and resilient growth; defensive pharma is not structurally threatened

→ vs conservative: Sentiment being uniformly positive as local top signal assumes tops form immediately; sentiment can stay positive for months or years in structural bull markets